A Study of Moderate to Severe Inflammatory Bowel Disease, Including Ulcerative Colitis (UC) and Crohn's Disease (CD)

CompletedOBSERVATIONAL
Enrollment

335

Participants

Timeline

Start Date

August 30, 2021

Primary Completion Date

May 17, 2022

Study Completion Date

May 17, 2022

Conditions
Inflammatory Bowel DiseasesColitis, UlcerativeCrohn Disease
Trial Locations (12)

14050

Hospital Medica Sur Tlalpan, Mexico City

14080

Instituto Nacional de Ciencias Medicas Y Nutricion Salvador Zubiran, Mexico City

27000

Unidad de Enfermedades Reumaticas y Cronico degenerativas, Torreón

27010

"Centro De Investigacion Clinica De Alta Especialidad Cicae", Torreón

44600

Endoamer S.C., Guadalajara

45138

CIMESAP Sociedad de Responsabilidad Limitada de Capital Variable, Zapopan

50120

Torre Medica Sanatorio Toluca, Toluca

64710

Fundacion Santos y de la Garza Evia, Monterrey

66220

Oncare Oncology, San Pedro Garza García

66278

Hospital Zambrano Hellion TecSalud, San Pedro Garza García

68020

Centro de Investigacion Clinica de Oaxaca, Oaxaca City

91910

Arke SMO S.A. De C.V, Veracruz

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Takeda

INDUSTRY